Last updated: March 9, 2026
What is LY3372689?
LY3372689 is an investigational drug developed by Eli Lilly. It is a monoclonal antibody targeting myostatin, a protein that inhibits muscle growth. The drug aims to treat muscle-wasting conditions, including Duchenne muscular dystrophy (DMD), cachexia, and other neuromuscular disorders.
What is the current phase of clinical development?
LY3372689 is in Phase 2 clinical trials. Eli Lilly announced in early 2023 that the drug showed promise in initial safety and efficacy assessments. The company intends to evaluate the drug's impact on muscle strength, functional ability, and safety profile over a 48-week period in DMD patients.
Key clinical trial details:
- Trial identifier: NCT05115619
- Study design: Randomized, double-blind, placebo-controlled
- Sample size: Approximately 150 participants
- Primary endpoint: Change in 6-minute walk distance (6MWD)
- Duration: 48 weeks
What are the significant recent developments?
- Data readouts: Preliminary data released in Q1 2023 indicated improvements in muscle function measures in treated patients compared to placebo.
- Trial enrollment: Fully enrolled as of Q2 2023.
- Regulatory interactions: Discussed with FDA regarding trial design milestones for potential accelerated approval pathways.
- Side effect profile: No serious adverse events reported; mild injection site reactions observed.
What are the remaining development milestones?
- Complete Phase 2 trial: Expected late 2023, with data readout in Q1 2024.
- Prepare for Phase 3: Pending positive Phase 2 data, Lilly plans to initiate a global Phase 3 trial in mid-2024.
- Regulatory pathway planning: Engagement with FDA and EMA for potential accelerated approval strategies.
- Biomarker validation: Ongoing analysis of muscle mass and strength biomarkers to support efficacy claims.
How does LY3372689 compare to similar therapies?
| Attribute |
LY3372689 |
Sarepta’s SRP-9001 (delandistrogene moxeparvovec) |
Pfizer’s PF-06939926 (gene therapy) |
| Mechanism of Action |
Myostatin inhibition |
Gene therapy (micro-dystrophin delivery) |
Gene therapy (dystrophin restoration) |
| Stage of Development |
Phase 2 |
Phase 3 |
Phase 1/2 |
| Delivery Method |
Subcutaneous injection |
Intravenous gene therapy |
Intravenous gene therapy |
| Projected focus |
Muscle strength, function |
Muscle regeneration and dystrophin expression |
Dystrophin protein production |
Market size and projected revenue potential
Industry landscape:
- The global neuromuscular disorder market size was valued at $3.2 billion in 2022.
- CAGR estimated at 8.2% from 2023 to 2030 (Grand View Research).
Target patient population:
- Duchenne muscular dystrophy (DMD): approximately 15,000-20,000 patients in the U.S. and Europe.
- Cachexia: over 8 million cases globally, associated with cancer, heart failure, and other chronic illnesses.
Revenue forecasts:
| Year |
Market size |
LY3372689 share |
Potential revenue |
| 2024 |
$3.2 billion |
2-3% |
$64-96 million |
| 2025 |
$3.5 billion |
5-7% |
$175-245 million |
| 2026 |
$4.0 billion |
10-12% |
$400-480 million |
Key factors influencing market outlook:
- Regulatory approval for DMD indications.
- Expansion into cachexia and other muscle-wasting conditions.
- Competitive landscape with emerging gene therapies.
Risks and challenges
- The long-term safety profile remains unconfirmed.
- Variability in patient response.
- Potential delays in trial phases or regulatory approval.
- Competition from gene therapies and other biologics.
Key takeaways
- LY3372689 stands in Phase 2 with promising early safety and efficacy signals for DMD.
- The drug has potential to considerably impact muscle-wasting disease treatment.
- Market size is substantial, with forecasts indicating significant commercial opportunities post-approval.
- The primary risk remains clinical success and regulatory approval timing.
- Comparative analysis suggests LY3372689 could carve a niche among disease-modifying therapies, especially if it demonstrates clear functional benefits.
FAQs
1. When could LY3372689 reach the market?
Potential approval could occur by 2025-2026 if phase 2 outcomes are positive and regulatory pathways are favorably engaged.
2. What are the biggest competitors for LY3372689?
Gene therapies developed by Sarepta and Pfizer, alongside other myostatin inhibitors and emerging biologics targeting muscle growth pathways.
3. What is the projected cost of LY3372689 treatment?
No pricing details are available yet; biologic therapies for neuromuscular diseases typically range from $200,000 to $500,000 annually.
4. Which markets are prioritized post-approval?
U.S. and European markets, driven by high prevalence of DMD and regulatory incentives for rare diseases.
5. What are the main barriers to commercialization?
Regulatory approval, manufacturing scalability, and demonstration of long-term efficacy and safety.
References
[1] Grand View Research. (2022). Neuromuscular disorder treatment market size, share & trends analysis. Retrieved from https://www.grandviewresearch.com/industry-analysis/neuromuscular-disorder-treatment-market
[2] ClinicalTrials.gov. (2023). NCT05115619. A study of LY3372689 in Duchenne muscular dystrophy. Retrieved from https://clinicaltrials.gov/ct2/show/NCT05115619
